Literature DB >> 25726258

A Common Source Outbreak of Severe Delirium Associated with Exposure to the Novel Synthetic Cannabinoid ADB-PINACA.

Michael D Schwartz1, Jordan Trecki2, Laura A Edison3, Alaina R Steck4, Justin K Arnold4, Roy R Gerona5.   

Abstract

BACKGROUND: Since 2009, synthetic cannabinoid (SC) use has emerged as a growing public health threat in the United States (US). Several outbreaks of unexpected, severe toxicity linked to SC use have been reported since 2012. Reports of varied and significant morbidity after SC use are expected to increase because newer compounds enter the marketplace more frequently as manufacturers attempt to circumvent regulatory efforts. CASE REPORT: We report a cluster of 7 patients who experienced a spectrum of anxiety, delirium, psychosis, and aggressive behaviors after smoking the same SC-containing product at a party. An 8th patient with the same exposure source presented with delayed onset seizures. Biologic samples were analyzed for novel, newly identified SCs belonging to the FUBINACA family of compounds. A previously unknown SC, N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA) was identified in biologic samples from 7 of the individuals. ADB-PINACA was identified in the SC-containing product ("Crazy Clown") seized by law enforcement and identified as the product smoked by the 8 patients in the reported cluster. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: The information compiled using this cluster of cases, and a similar reported outbreak of altered mental status in Colorado, implicating the same SC (ADB-PINACA) and brands of SC-containing products, aided the US Drug Enforcement Administration in its temporary scheduling of ADB-PINACA and three other SCs. In this outbreak, close cooperation between public health and law enforcement allowed for a rapid intervention, which halted the outbreak by interrupting the common source and accelerated regulatory efforts to prevent further morbidity and mortality. Published by Elsevier Inc.

Entities:  

Keywords:  ADB-PINACA; DEA scheduling; K2; cluster; delirium; outbreak; spice; synthetic cannabinoid

Mesh:

Substances:

Year:  2015        PMID: 25726258      PMCID: PMC9049074          DOI: 10.1016/j.jemermed.2014.12.038

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.473


  24 in total

1.  Convulsions associated with the use of a synthetic cannabinoid product.

Authors:  Aaron B Schneir; Todd Baumbacher
Journal:  J Med Toxicol       Date:  2012-03

2.  Myocardial infarction associated with use of the synthetic cannabinoid K2.

Authors:  Arshid Mir; Adebisi Obafemi; Amy Young; Colin Kane
Journal:  Pediatrics       Date:  2011-11-07       Impact factor: 7.124

3.  Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples.

Authors:  Sebastian Dresen; Stefan Kneisel; Wolfgang Weinmann; Ralf Zimmermann; Volker Auwärter
Journal:  J Mass Spectrom       Date:  2011-01-24       Impact factor: 1.982

4.  Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism.

Authors:  Melanie Hutter; Bjoern Moosmann; Stefan Kneisel; Volker Auwärter
Journal:  J Mass Spectrom       Date:  2013-07       Impact factor: 1.982

5.  Development and validation of a liquid chromatography-tandem mass spectrometry method for the identification and quantification of JWH-018, JWH-073, JWH-019, and JWH-250 in human whole blood.

Authors:  Sherri L Kacinko; Allan Xu; Joseph W Homan; Matthew M McMullin; Donna M Warrington; Barry K Logan
Journal:  J Anal Toxicol       Date:  2011-09       Impact factor: 3.367

6.  AKI associated with synthetic cannabinoids: a case series.

Authors:  Gautam Kantilal Bhanushali; Gaurav Jain; Huma Fatima; Leah J Leisch; Denyse Thornley-Brown
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-14       Impact factor: 8.237

7.  Synthetic cannabinoid intoxication: a case series and review.

Authors:  Carson R Harris; Ashley Brown
Journal:  J Emerg Med       Date:  2012-09-16       Impact factor: 1.484

8.  A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010.

Authors:  Christopher O Hoyte; Jeena Jacob; Andrew A Monte; Mohammed Al-Jumaan; Alvin C Bronstein; Kennon J Heard
Journal:  Ann Emerg Med       Date:  2012-05-09       Impact factor: 5.721

9.  Notes from the field: Severe illness associated with synthetic cannabinoid use - Brunswick, Georgia, 2013.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-11-22       Impact factor: 17.586

10.  Acute kidney injury associated with synthetic cannabinoid use--multiple states, 2012.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-02-15       Impact factor: 17.586

View more
  25 in total

1.  Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences.

Authors:  Brian F Thomas; Timothy W Lefever; Ricardo A Cortes; Megan Grabenauer; Alexander L Kovach; Anderson O Cox; Purvi R Patel; Gerald T Pollard; Julie A Marusich; Richard C Kevin; Thomas F Gamage; Jenny L Wiley
Journal:  J Pharmacol Exp Ther       Date:  2017-01-13       Impact factor: 4.030

2.  Cannabinoid-like effects of five novel carboxamide synthetic cannabinoids.

Authors:  Michael B Gatch; Michael J Forster
Journal:  Neurotoxicology       Date:  2018-11-12       Impact factor: 4.294

3.  Death Associated With the Use of the Synthetic Cannabinoid ADB-FUBINACA.

Authors:  Kevin G Shanks; William Clark; George Behonick
Journal:  J Anal Toxicol       Date:  2016-01-10       Impact factor: 3.367

Review 4.  The Bridge Between Classical and "Synthetic"/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective.

Authors:  Laura Orsolini; Stefania Chiappini; Duccio Papanti; Domenico De Berardis; John M Corkery; Fabrizio Schifano
Journal:  Front Psychiatry       Date:  2019-11-20       Impact factor: 4.157

5.  Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18.

Authors:  Richard C Kevin; Timothy W Lefever; Rodney W Snyder; Purvi R Patel; Thomas F Gamage; Timothy R Fennell; Jenny L Wiley; Iain S McGregor; Brian F Thomas
Journal:  Drug Test Anal       Date:  2017-09-28       Impact factor: 3.345

6.  Δ(9)-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids in mice and rats.

Authors:  Michael B Gatch; Michael J Forster
Journal:  Psychopharmacology (Berl)       Date:  2016-02-15       Impact factor: 4.530

7.  Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro Assays.

Authors:  T W Grim; A J Morales; M M Gonek; J L Wiley; B F Thomas; G W Endres; L J Sim-Selley; D E Selley; S S Negus; A H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2016-08-17       Impact factor: 4.030

8.  Quantitation of Synthetic Cannabinoid Receptor Agonists in Postmortem Blood Using a Single Point Calibration.

Authors:  Phoebe Sharp; Simon Hudson; Stephen R Morley
Journal:  Acad Forensic Pathol       Date:  2021-07-20

9.  Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.

Authors:  Thomas F Gamage; Charlotte E Farquhar; Timothy W Lefever; Julie A Marusich; Richard C Kevin; Iain S McGregor; Jenny L Wiley; Brian F Thomas
Journal:  J Pharmacol Exp Ther       Date:  2018-03-16       Impact factor: 4.030

10.  Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures.

Authors:  Richard C Kevin; Alexander L Kovach; Timothy W Lefever; Thomas F Gamage; Jenny L Wiley; Iain S McGregor; Brian F Thomas
Journal:  Forensic Toxicol       Date:  2018-06-28       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.